PHARMARESOURCES (SHANGHAI) CO., LTD. Financials PharmaResources (Shanghai) Co., Ltd.
Equities
301230
CNE1000065Q9
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.24 CNY | +1.92% |
|
+1.60% | -19.24% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 4,107 | 3,853 | 3,086 | - | - |
| Enterprise Value (EV) 1 | 4,107 | 3,853 | 3,086 | 3,086 | 3,086 |
| P/E ratio | 48.6 x | 102 x | 48.3 x | 43.6 x | 32.7 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 8.58 x | 7.87 x | 5.5 x | 4.57 x | 3.74 x |
| EV / Revenue | 8.58 x | 7.87 x | 5.5 x | 4.57 x | 3.74 x |
| EV / EBITDA | 41.7 x | 54.1 x | 30 x | 24.3 x | 19.3 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | 3.69 x | 3.45 x | 2.71 x | 2.59 x | 2.44 x |
| Nbr of stocks (in thousands) | 139,909 | 139,909 | 138,769 | - | - |
| Reference price 2 | 29.35 | 27.54 | 22.24 | 22.24 | 22.24 |
| Announcement Date | 4/21/23 | 4/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 478.9 | 489.7 | 561 | 676 | 825 |
| EBITDA 1 | - | 98.45 | 71.21 | 103 | 127 | 160 |
| EBIT 1 | - | 72.85 | 37.44 | 70 | 78 | 102 |
| Operating Margin | - | 15.21% | 7.65% | 12.48% | 11.54% | 12.36% |
| Earnings before Tax (EBT) 1 | - | 72.92 | 36.76 | 69 | 78 | 102 |
| Net income 1 | 73.58 | 67.18 | 37.62 | 64 | 72 | 94 |
| Net margin | - | 14.03% | 7.68% | 11.41% | 10.65% | 11.39% |
| EPS 2 | 0.7033 | 0.6044 | 0.2692 | 0.4600 | 0.5100 | 0.6800 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/14/22 | 4/21/23 | 4/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 |
|---|---|
| Net sales 1 | 130.7 |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | 3.668 |
| Net margin | 2.81% |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 4/25/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 13.4% | 3.39% | 5.6% | 6% | 7.4% |
| ROA (Net income/ Total Assets) | - | - | 2.7% | 4.1% | 4.2% | 5.2% |
| Assets 1 | - | - | 1,394 | 1,561 | 1,714 | 1,808 |
| Book Value Per Share 2 | - | 7.950 | 7.990 | 8.210 | 8.580 | 9.110 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 124 | 248 | 108 | 90 | 72 |
| Capex / Sales | - | 25.89% | 50.69% | 19.25% | 13.31% | 8.73% |
| Announcement Date | 4/14/22 | 4/21/23 | 4/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
22.24
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.24% | 425M | |
| +25.83% | 47.96B | |
| +46.00% | 41.47B | |
| +0.69% | 42.45B | |
| +30.52% | 31.6B | |
| +22.30% | 28.63B | |
| -6.35% | 28.03B | |
| +49.25% | 14.56B | |
| +49.18% | 14.14B | |
| +3.45% | 12.58B |
- Stock Market
- Equities
- 301230 Stock
- Financials PharmaResources (Shanghai) Co., Ltd.
